A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Trial Profile

A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Algenpantucel-L (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PILLAR
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 15 Dec 2015 Status changed from recruiting to active, no longer recruiting, as per NewLink media release.
    • 29 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 26 Feb 2015 According to a NewLink Genetics Corporation media release, enrolment is expected to be complete in second half of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top